Background
Pozen Inc. held patents covering VIMOVO® — a combination product containing naproxen (a common nonsteroidal anti-inflammatory drug, or NSAID) and esomeprazole (a proton pump inhibitor) in a single tablet, designed to provide effective pain relief while reducing the gastropathy (stomach and GI damage) commonly caused by NSAIDs. The combination allowed patients who needed long-term NSAID therapy for arthritis or other pain to be protected from GI side effects by the co-administered PPI in the same pill.
Par Pharmaceutical filed an ANDA seeking to market a generic version of VIMOVO. Pozen sued, and Par challenged the patents as obvious — arguing that combining an NSAID with a PPI for gastroprotection was a well-known clinical practice, and that the specific claimed combination and dosing approach was predictable from the prior art. The district court agreed and found the patents obvious. Pozen appealed.
The Court’s Holding
The Federal Circuit reversed the obviousness finding. While the prior art established the general concept of co-administering NSAIDs with PPIs for gastroprotection, the specific claimed dosing regimen — the particular combination of delayed-release naproxen with immediate-release esomeprazole optimized for both efficacy and safety — was not shown to be an obvious combination at the time of filing. The district court had improperly aggregated broad prior art teachings about NSAID/PPI co-administration without carefully analyzing the specific motivation to arrive at the precise claimed formulation and dosing parameters.
The court also found that the district court had inadequately credited the secondary considerations evidence, including commercial success of VIMOVO and evidence that clinicians had long sought but failed to achieve an effective combined product that maintained adequate NSAID activity while providing meaningful gastroprotection. These objective indicia supported non-obviousness and should have been given greater weight in the analysis.
Key Takeaways
- General clinical knowledge that two drug classes can be co-administered does not make obvious a specific fixed-dose combination product with a particular dosing regimen — the motivation to combine must be tied to the specific claimed formulation, not just the general concept of combination therapy.
- Method-of-treatment claims covering specific dosing regimens can be non-obvious even when the individual drugs are well-known, if the specific combination and dosing parameters represent a genuine advance over what practitioners had previously achieved.
- Secondary considerations evidence — including evidence that patients or practitioners sought but failed to achieve the claimed therapeutic result — must be given proper weight and cannot be dismissed without specific factual findings.
- Post-KSR obviousness in pharmaceutical combination therapy cases requires specific analysis of the motivation to combine the precise claimed elements, not general reasoning about what classes of drugs might be usefully combined.
Why It Matters
Pozen v. Par Pharmaceutical was an important decision for the pharmaceutical fixed-dose combination product space — a growing area of drug development in which companies combine existing active ingredients in ways that improve patient compliance, reduce pill burden, or address known side effect profiles. The ruling reinforced that even when the components of a combination are well-known and the general concept of combination therapy is understood, the specific dosing and formulation choices that make a combination product clinically effective can be patentable if they represent a genuine inventive contribution beyond what the prior art taught.
The case is also significant for its treatment of secondary considerations in pharmaceutical combination patents — particularly evidence that clinicians had recognized the need for the specific product and had failed to achieve the claimed combination on their own. This type of evidence, when properly documented and presented, can provide decisive support for non-obviousness in Hatch-Waxman challenges where the patent appears at first glance to be a combination of known elements.